期刊文献+

阿司匹林联合灯盏细辛对2型糖尿病合并冠心病心率变异性的影响 被引量:3

下载PDF
导出
摘要 目的评探讨阿司匹林联合灯盏细辛对2型糖尿病合并冠心病心率变异性的影响。方法选择我院2017年1月-2018年10月收治入院的T2DM合并冠心病患者150例作为研究对象,随机分为三组,每组50例,灯盏细辛联合辛伐他汀治疗组(A组),阿司匹林联合辛伐他汀治疗组(B组)和阿司匹林+灯盏细辛+辛伐他汀治疗组(C组)。观察三组的治疗效果,记录心绞痛每日发作次数及持续时间,记录12导联心电图每日变化情况,记录治疗前后心率变异性指标的变化。结果三组患者治疗前SDANN、SDNN、RMSSD、SDNNI、PNN50%、MeanHR等指标无统计学差异(P>0.05);C组患者治疗后SDANN、SDNN、RMSSD、SDNNI、PNN50%、MeanHR等心率变异性指标与组内治疗前、A、B两组治疗后比较差异均有统计学意义(P<0.05);C组患者临床总有效率为94.0%,明显高于A、B两组62.0%、72.0%,比较差异均有统计学意义(P<0.05)。结论阿司匹林联合灯盏细辛治疗2型糖尿病合并冠心病效果好,可明显提高疗效,改善心率变异性。
机构地区 兴宁市人民医院
出处 《心电图杂志(电子版)》 2019年第1期77-78,共2页 Journal of Electrocardiogram(Electronic Edition)
  • 相关文献

参考文献6

二级参考文献87

  • 1胡大一,孙艺红.正确认识阿司匹林“抵抗”[J].中华心血管病杂志,2006,34(12):1057-1058. 被引量:10
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南[Z].2010.
  • 3侯传启,田家运.冠心病合并2型糖尿病患者冠状动脉造影特点分析[J].河北医学,2007,13(10):1173-1175. 被引量:1
  • 4Yang WY , Lu JM, Weng JP, et al. Prevalence of Diabetes a- mong Menand Women in China. N Engl J Med, 2010,362 : 1090- 1011.
  • 5Thattacharyya OK, Shah BR, Booth GL. Management of cardio- vascular disease in patients with diabetes:the 2008 Canadian Di- abetes Association guidelines. CMAJ, 2008,179 : 920-926.
  • 6Executive Summary of The Third Report of The National Cho lesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In A- dults (Adult Treatment Panel III). JAMA, 2001, 285: 2486-2497.
  • 7American Diabetes Association. Executive summary: Standards of medical care in diabetes-2014. Diabetes Care, 2014,37 Suppl1 : $14-$80.
  • 8Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) :The i{th joint task force of the european society of car- diology and other societies on cardiovascular disease preven'don in clinical practice (constituted by representatives o{ nine socie- ties and by invited experts). G Ital Cardiol (Rome), 2013,14: 328-392.
  • 9Diabetes Australia Guideline Development Consortium, National Medical Research Council[EB/OL]. National Evidence Based Guidelines for the Management of Type 2 Diabetes Mellitus,in Part 5, Prevention and Detection of Macrovaseular Disease in Type 2 Diabetes 2004, Australian Centre for Diabetes Strate- gies: Sydney, Australia. (2014-11-11)http://www. nhmrc, gov. cn/guidelines-publieations/di7 diS-di10-dill-di12-di13, html.
  • 10Nationwide Assessment of Cardiovascular Risk Factors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients with Type 2 Diabetes CCMR - 3B STUDY[EB/OL]www. elinicaltrials, gov, NCT01128205, Supported in part by a re- search grant from Merck Sharp Dohme (China) Ltd. (2014-11 11) http://www, hhmrc, gov. cn/guidelines-publieations/di7- diS-dil0 dill-dil2-dil3, html.

共引文献64

同被引文献42

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部